A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.
Epistemonikos ID: edf67a4952518ec68f11cab72f85449ce509566a
First added on: May 08, 2024